Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies.

Huttner NA, Girod A, Perabo L, Edbauer D, Kleinschmidt JA, Büning H, Hallek M.

Gene Ther. 2003 Dec;10(26):2139-47.

PMID:
14625569
2.

Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure.

Moskalenko M, Chen L, van Roey M, Donahue BA, Snyder RO, McArthur JG, Patel SD.

J Virol. 2000 Feb;74(4):1761-6.

3.

Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice.

Scallan CD, Jiang H, Liu T, Patarroyo-White S, Sommer JM, Zhou S, Couto LB, Pierce GF.

Blood. 2006 Mar 1;107(5):1810-7. Epub 2005 Oct 25.

4.

Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization.

Lochrie MA, Tatsuno GP, Christie B, McDonnell JW, Zhou S, Surosky R, Pierce GF, Colosi P.

J Virol. 2006 Jan;80(2):821-34.

6.

Engineering adeno-associated virus serotype 2-based targeting vectors using a new insertion site-position 453-and single point mutations.

Boucas J, Lux K, Huber A, Schievenbusch S, von Freyend MJ, Perabo L, Quadt-Humme S, Odenthal M, Hallek M, Büning H.

J Gene Med. 2009 Dec;11(12):1103-13. doi: 10.1002/jgm.1392.

PMID:
19777441
7.

Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.

Zaiss AK, Muruve DA.

Gene Ther. 2008 Jun;15(11):808-16. doi: 10.1038/gt.2008.54. Epub 2008 Apr 3. Review.

PMID:
18385765
8.

Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential.

Li Q, Miller R, Han PY, Pang J, Dinculescu A, Chiodo V, Hauswirth WW.

Mol Vis. 2008 Sep 24;14:1760-9.

9.

Immune responses to adeno-associated virus vectors.

Zaiss AK, Muruve DA.

Curr Gene Ther. 2005 Jun;5(3):323-31. Review.

PMID:
15975009
10.

Vectors selected from adeno-associated viral display peptide libraries for leukemia cell-targeted cytotoxic gene therapy.

Michelfelder S, Lee MK, deLima-Hahn E, Wilmes T, Kaul F, Müller O, Kleinschmidt JA, Trepel M.

Exp Hematol. 2007 Dec;35(12):1766-76. Epub 2007 Oct 17.

PMID:
17920758
11.

Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands.

Aldrich WA, Ren C, White AF, Zhou SZ, Kumar S, Jenkins CB, Shaw DR, Strong TV, Triozzi PL, Ponnazhagan S.

Gene Ther. 2006 Jan;13(1):29-39.

PMID:
16136165
12.

Immune responses to AAV in clinical trials.

Mingozzi F, High KA.

Curr Gene Ther. 2007 Oct;7(5):316-24. Review.

PMID:
17979678
13.

Insertional mutagenesis of AAV2 capsid and the production of recombinant virus.

Rabinowitz JE, Xiao W, Samulski RJ.

Virology. 1999 Dec 20;265(2):274-85.

14.

Receptor targeting of adeno-associated virus vectors.

Büning H, Ried MU, Perabo L, Gerner FM, Huttner NA, Enssle J, Hallek M.

Gene Ther. 2003 Jul;10(14):1142-51. Review.

PMID:
12833123
16.

Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes.

Maersch S, Huber A, Büning H, Hallek M, Perabo L.

Virology. 2010 Feb 5;397(1):167-75. doi: 10.1016/j.virol.2009.10.021. Epub 2009 Nov 18.

17.
18.

Addition of six-His-tagged peptide to the C terminus of adeno-associated virus VP3 does not affect viral tropism or production.

Zhang HG, Xie J, Dmitriev I, Kashentseva E, Curiel DT, Hsu HC, Mountz JD.

J Virol. 2002 Dec;76(23):12023-31.

20.

Supplemental Content

Support Center